Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections

NCT01232595 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

109

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate Clostridium Difficile Infection

Interventions

DRUG: LFF571
DRUG: Vancomycin (POC)

Sponsor

Novartis Pharmaceuticals